vs
Side-by-side financial comparison of Douglas Elliman Inc. (DOUG) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Douglas Elliman Inc. is the larger business by last-quarter revenue ($245.4M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). Douglas Elliman Inc. runs the higher net margin — 27.9% vs 1.6%, a 26.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 0.9%). Over the past eight quarters, Douglas Elliman Inc.'s revenue compounded faster (10.7% CAGR vs -0.2%).
Douglas Elliman Inc. is a leading U.S.-based residential real estate brokerage firm. It offers luxury property sales, rentals, property management, and advisory solutions, serving high-net-worth clients across key metro markets including New York, California, Florida, and Texas.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DOUG vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $245.4M | $177.4M |
| Net Profit | $68.6M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 27.3% | 3.9% |
| Net Margin | 27.9% | 1.6% |
| Revenue YoY | 0.9% | 5.0% |
| Net Profit YoY | 1243.4% | — |
| EPS (diluted) | $0.80 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $245.4M | $196.9M | ||
| Q3 25 | $262.8M | $179.5M | ||
| Q2 25 | $271.4M | $181.1M | ||
| Q1 25 | $253.4M | $168.9M | ||
| Q4 24 | $243.3M | $187.3M | ||
| Q3 24 | $266.3M | $168.6M | ||
| Q2 24 | $285.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $68.6M | — | ||
| Q3 25 | $-24.7M | $5.4M | ||
| Q2 25 | $-22.7M | $-4.8M | ||
| Q1 25 | $-6.0M | $4.8M | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-27.2M | $-143.5M | ||
| Q2 24 | $-1.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 27.3% | 1.2% | ||
| Q3 25 | -4.1% | 3.5% | ||
| Q2 25 | -2.0% | 4.7% | ||
| Q1 25 | -2.1% | 1.2% | ||
| Q4 24 | -6.7% | 13.2% | ||
| Q3 24 | -2.8% | -82.8% | ||
| Q2 24 | -1.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 27.9% | — | ||
| Q3 25 | -9.4% | 3.0% | ||
| Q2 25 | -8.4% | -2.7% | ||
| Q1 25 | -2.4% | 2.8% | ||
| Q4 24 | -2.5% | — | ||
| Q3 24 | -10.2% | -85.1% | ||
| Q2 24 | -0.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.80 | $0.05 | ||
| Q3 25 | $-0.29 | $0.12 | ||
| Q2 25 | $-0.27 | $-0.11 | ||
| Q1 25 | $-0.07 | $0.10 | ||
| Q4 24 | $-0.06 | $0.38 | ||
| Q3 24 | $-0.33 | $-3.11 | ||
| Q2 24 | $-0.02 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $115.5M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $183.9M | $653.9M |
| Total Assets | $444.4M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $115.5M | $238.4M | ||
| Q3 25 | $143.0M | $246.3M | ||
| Q2 25 | $136.3M | $445.9M | ||
| Q1 25 | $136.8M | $493.6M | ||
| Q4 24 | $145.5M | $484.6M | ||
| Q3 24 | $151.4M | $453.8M | ||
| Q2 24 | $92.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $183.9M | $693.1M | ||
| Q3 25 | $115.1M | $727.2M | ||
| Q2 25 | $137.6M | $757.8M | ||
| Q1 25 | $158.2M | $798.5M | ||
| Q4 24 | $162.2M | $778.3M | ||
| Q3 24 | $173.6M | $749.6M | ||
| Q2 24 | $196.9M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $444.4M | $1.3B | ||
| Q3 25 | $480.6M | $1.3B | ||
| Q2 25 | $489.0M | $1.5B | ||
| Q1 25 | $493.9M | $1.6B | ||
| Q4 24 | $493.9M | $1.6B | ||
| Q3 24 | $502.7M | $1.5B | ||
| Q2 24 | $463.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | — |
| Free Cash FlowOCF − Capex | $-14.7M | — |
| FCF MarginFCF / Revenue | -6.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | -0.21× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-17.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-14.4M | $43.7M | ||
| Q3 25 | $5.5M | $60.8M | ||
| Q2 25 | $642.0K | $12.0M | ||
| Q1 25 | $-5.6M | $35.5M | ||
| Q4 24 | $-9.0M | $33.1M | ||
| Q3 24 | $9.0M | $53.9M | ||
| Q2 24 | $1.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-14.7M | $43.5M | ||
| Q3 25 | $4.7M | $57.0M | ||
| Q2 25 | $-575.0K | $9.3M | ||
| Q1 25 | $-6.7M | $26.9M | ||
| Q4 24 | $-10.2M | $31.0M | ||
| Q3 24 | $7.7M | $49.8M | ||
| Q2 24 | $432.0K | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -6.0% | 22.1% | ||
| Q3 25 | 1.8% | 31.7% | ||
| Q2 25 | -0.2% | 5.1% | ||
| Q1 25 | -2.6% | 15.9% | ||
| Q4 24 | -4.2% | 16.6% | ||
| Q3 24 | 2.9% | 29.6% | ||
| Q2 24 | 0.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.3% | 2.2% | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 0.4% | 5.1% | ||
| Q4 24 | 0.5% | 1.1% | ||
| Q3 24 | 0.5% | 2.4% | ||
| Q2 24 | 0.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | -0.21× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
